Jeffrey Weber

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in ...

European journal of cancer (Oxford, England : 1990) · 2 mei 2025

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024-11

Systemische therapie bij melanoom: ASCO 2023 richtlijn update

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2023

Adjuvant nivolumab versus ipilimumab bij melanoom: CheckMate 238 vierjaars herbeoordeling

European journal of cancer (Oxford, England : 1990) · 2022-09

Systemische therapie bij melanoom: ASCO 2020 richtlijn

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 november 2020

Adjuvant nivolumab versus ipilimumab bij melanoom: CheckMate 238 vierjaars

The Lancet. Oncology · 2020-11

Langetermijnuitkomsten van dabrafenib-trametinib bij BRAF V600-gemuteerd melanoom: vijfjaarsdata

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 maart 2018

Totale overleving van nivolumab versus chemotherapie bij melanoom: CheckMate 037 update

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 februari 2018

Adjuvant nivolumab versus ipilimumab bij gereseceerd stadium III/IV melanoom: CheckMate 238

The New England journal of medicine · 9 november 2017

Publicaties op Oncologisch.com